Thermo Fisher Scientific
On Monday, shares in Massachusetts headquartered Thermo Fisher Scientific Inc. recorded a trading volume of 1.61 million shares, which was above their three months average volume of 1.37 million shares. The stock ended the day at $150.78, which was a slight correction of 0.61%. The Company's shares have gained 0.49% in the last one month and 6.63% on an YTD basis. The stock is trading above its 200-day moving average by 3.49%. Furthermore, shares of Thermo Fisher Scientific, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide, have a Relative Strength Index (RSI) of 39.03.
On September 22nd, 2016, research firm JP Morgan resumed its 'Overweight' rating on the Company's stock, issuing a target price of $180 per share.
On October 17th, 2016, the company announced that it has joined the Cancer Moonshot, an initiative led by Vice President Joe Biden aimed at making more therapies available to more patients while also improving cancer detection at early stages and, ultimately, preventing the disease. Initially, Thermo Fisher will join a liquid biopsy-based precision oncology pilot, called the Blood Profiling Atlas designed to make it easier for oncologists to access databases of liquid biopsy information when diagnosing patients. Your complete research report on TMO can be retrieved for free at:
Massachusetts headquartered Bruker Corp.'s stock finished yesterday's session 0.66% higher at $21.28 and with a total trading volume of 417,701 shares. Shares of the Company, which together with its subsidiaries, designs and manufactures scientific instruments, and analytical and diagnostic solutions worldwide, are trading below their 50-day moving average by 3.93%. The stock has an RSI of 38.97.
On September 25th, 2016, Bruker announced that it has expanded its license agreement with 3M for processing of FFPE tissue sections. Mass spectrometric imaging by MALDI-TOF is the leading mass spectrometric method for the analysis of tissues, such as Formalin Fixed Paraffin Embedded (FFPE) tissues. Bruker and 3M have agreed to extend Bruker´s global license for 3M´s patent from research to routine use. This is an important step towards developing future product offerings for anatomical pathology laboratories, including clinically validated content libraries for specific clinical indications. The license rights now cover the acquisition of MALDI spectra from FFPE sections for research and routine applications. BRKR free report is just a click away at:
At the closing bell on Monday, shares in Pennsylvania-based VWR Corp. rose 0.11%, ending the day at $27.53. The stock recorded a trading volume of 439,494 shares. The Company's shares are trading 0.73% above their 200-day moving average. Moreover, shares of VWR Corp., which together with its subsidiaries, operates as an independent provider of laboratory products, services, and solutions to the life science, general research, and applied markets, have an RSI of 39.48.
On October 7th, 2016, VWR announced that it will release its Q3 2016 financial results on November 3rd, 2016, before the market opens. An investor conference call and live webcast will be hosted by the company's management team that same day at 8:00 AM ET. Sign up for your complimentary research report on VWR at:
Laboratory Corp. of America
Laboratory Corp. of America Holdings' stock ended the day 0.13% higher at $135.97 and with a total trading volume of 298,746 shares. The Company's shares have gained 0.44% in the last month and 9.97% on an YTD basis. The stock is trading 8.36% above its 200-day moving average. Additionally, shares of Laboratory Corp. of America (LabCorp), which operates as an independent clinical laboratory company worldwide, have an RSI of 46.14.
On October 3rd, 2016, the company announced that its Zero Coupon Convertible Subordinated Notes due 2021 are convertible into cash and LabCorp's Common Stock, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24th, 2006, between LabCorp and The Bank of New York Mellon, as trustee and the conversion agent. In order to exercise the option to convert all or a portion of the Zero Coupon Notes, holders must validly surrender their Zero Coupon Notes at any time during the calendar quarter through the close of business at 5:00 p.m., ET, on December 30th, 2016. Register for free on Stock-Callers.com and download the latest research report on LH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA